McKesson/$MCK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About McKesson
McKesson Corp is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Ticker
$MCK
Sector
Primary listing
NYSE
Employees
44,000
Headquarters
Website
McKesson Metrics
BasicAdvanced
$99B
31.74
$24.95
0.51
$2.95
0.41%
Price and volume
Market cap
$99B
Beta
0.51
52-week high
$792.34
52-week low
$492.39
Average daily volume
722K
Dividend rate
$2.95
Financial strength
Current ratio
0.883
Quick ratio
0.475
Long term debt to equity
-971.842
Total debt to equity
-1,150.985
Dividend payout ratio (TTM)
11.16%
Interest coverage (TTM)
20.55%
Profitability
EBITDA (TTM)
5,401
Gross margin (TTM)
3.45%
Net profit margin (TTM)
0.84%
Operating margin (TTM)
1.30%
Effective tax rate (TTM)
22.52%
Revenue per employee (TTM)
$8,580,000
Management effectiveness
Return on assets (TTM)
4.01%
Return on equity (TTM)
-298.75%
Valuation
Price to earnings (TTM)
31.735
Price to revenue (TTM)
0.265
Price to book
-50.33
Price to tangible book (TTM)
-5.62
Price to free cash flow (TTM)
17.635
Free cash flow yield (TTM)
5.67%
Free cash flow per share (TTM)
44.906
Dividend yield (TTM)
0.37%
Forward dividend yield
0.41%
Growth
Revenue change (TTM)
20.35%
Earnings per share change (TTM)
11.87%
3-year revenue growth (CAGR)
12.04%
10-year revenue growth (CAGR)
7.51%
3-year earnings per share growth (CAGR)
39.24%
10-year earnings per share growth (CAGR)
13.56%
3-year dividend per share growth (CAGR)
14.74%
10-year dividend per share growth (CAGR)
11.46%
What the Analysts think about McKesson
Analyst ratings (Buy, Hold, Sell) for McKesson stock.
Bulls say / Bears say
McKesson raised its fiscal 2026 profit forecast and beat Wall Street revenue and EPS estimates in Q1, reporting $97.83 billion in revenue (consensus $96.08 billion) and adjusted EPS of $8.26 (consensus $8.15), driven by robust demand for specialty medicines (Reuters).
The company lifted its full-year fiscal 2026 adjusted EPS guidance range to $38.05–$38.55, up from $37.10–$37.90, citing strategic emphasis on high-margin oncology and multispecialty segments and raising long-term earnings growth targets to 13%–16% (Reuters).
McKesson’s recent acquisitions have strengthened its specialty and oncology distribution platform, contributing to the segment’s growth and supporting profitability recovery (Reuters).
A June 12, 2025 remittitur in the Baltimore opioid litigation reduced McKesson’s liability to $37 million, but the case remains active and could result in additional damages or a retrial if the city seeks further appeals (SEC 10-Q filing).
McKesson operates with razor-thin profit margins of approximately 1%, leaving its earnings highly sensitive to inflationary cost pressures, reimbursement rate changes, or supply chain disruptions (Barron's).
Trading at around 19 times forward earnings—near the upper end of its historical range—McKesson’s valuation offers limited downside protection and is vulnerable to a multiple contraction if specialty growth expectations are not met (Barron's).
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
McKesson Financial Performance
Revenues and expenses
McKesson Earnings Performance
Company profitability
McKesson News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for McKesson stock?
McKesson (MCK) has a market cap of $99B as of October 16, 2025.
What is the P/E ratio for McKesson stock?
The price to earnings (P/E) ratio for McKesson (MCK) stock is 31.74 as of October 16, 2025.
Does McKesson stock pay dividends?
Yes, the McKesson (MCK) stock pays dividends to shareholders. As of October 16, 2025, the dividend rate is $2.95 and the yield is 0.41%. McKesson has a payout ratio of 11.16% on a trailing twelve-month basis.
When is the next McKesson dividend payment date?
The next McKesson (MCK) dividend payment date is unconfirmed.
What is the beta indicator for McKesson?
McKesson (MCK) has a beta rating of 0.51. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.